Cidara Therapeutics Inc

Cidara Therapeutics — Investor Presentation (January 2017)

34 slides from Cidara Therapeutics's investor presentation, Jan 9, 2017

  1. Slide 1: New Hope For Serious Infections

    New Hope For Serious Infections Corporate Presentation January 2017 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements These slides and the accompanying oral presentation (the “Presentation”) contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ

  3. Slide 3: Two Platforms, Multiple Programs

    Two Platforms, Multiple Programs CD101 topical for VVC, Phase 2 CD101 IV for candidemia, Phase 2 CD101 Echinocandin Antifungal In-vivo proof of concept: antifungal Development candidate: antibacterial Volker Brinkmann, Wikimedia.org Cloudbreak™ Immunotherapy

  4. Slide 4: Fungal Infections: High Mortality

    U.S. 12-Week Mortality per Annum by Species Fungal Infections: High Mortality Rare Fungi Cryptococcus Aspergillus Candida 2,500 4,500 22,500 67,500 97,000 deaths per year

  5. Slide 5: Echinocandins: First Line Therapy for Candidemia

    Echinocandins: First Line Therapy for Candidemia DRUG PROFILE First line treatment for Candida Safe and well tolerated Superior to azoles BUT CONSTRAINED Once daily IV Low exposure — suboptimal dosing Growing resistance USD Billions 4.2 0.5 Polyenes 1.1 Echinocandins 2.6 Azoles

  6. Slide 6: CD101 Opportunity: Expand Echinocandin Market

    CD101 Opportunity: Expand Echinocandin Market ACCESS ENTIRE >$4 BILLION MARKET Inpatient & outpatient Treatment & prophylaxis Penetrate azole class Expand indications 1.1 2.6 0.5 4.2 Polyenes Echinocandins Azoles ~2x USD Billions

  7. Slide 7: CD101 — A Differentiated Echinocandin

    CD101 — A Differentiated Echinocandin ICAAC 2015 Prolongs PK Allows high exposures Eliminates toxic degradation products Enables multiple formulations once weekly dosing in clinical studies potential for improved efficacy potential for improved safety systemic and topical Structural modification yie

  8. Slide 8: CD101 IV: Streamlined Development Plan

    CD101 IV: Streamlined Development Plan PK and safety in healthy volunteers Double-blind vs. echinocandin in candidemia Phase I Phase II Non-inferiority vs. echinocandin in candidemia IND I II III Phase III + invasive candidiasis

  9. Slide 9: Summary — CD101 IV Phase 1 SAD/MAD Studies

    Summary — CD101 IV Phase 1 SAD/MAD Studies No serious AEs No withdrawals due to AEs PK was dose -proportional and supports once weekly dosing No clinically significant laboratory abnormalities in any CD101 subject Adverse Events (AEs): CD101 well tolerated CD101 IV was safe and well-tolerated up to

  10. Slide 10: CD101 IV Phase 1 PK

    AUC ~2.5x greater AUC ~1.6x higher Once Weekly High Exposure Dosing CD101 IV Phase I PK Cmax 3x higher Anidulafungin 100mg x 7 CD101 400mg x 1

  11. Slide 11: Phase 2 Candidemia Study

    Phase 2 Candidemia Study CD101 IV 400/400/(400)mg 1 8 Dosing day 15 (optional) 5 Mycological response 14 Mycological & Clinical response 1o END POINT Mycological & Clinical response 45-52 n=30 CD101 IV 400/200/(200)mg 1 8 Dosing day 15 (optional) 5 14 45-52 n=30 1 7 14 21 28 1 7 14 21 28 Caspofungin

  12. Slide 12: Clear CD101 Opportunity In Each Setting

    186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 U.S. Days of Therapy (Millions) U.S. Outpatient Prophylaxis U.S. Inpatient Hospital U.S. Discharge Clear CD101 Opportunity In Each Setting 1.5M DoT (12%) GI/More Invasive IC & Early Discharge 1.0M DoT (20%) Continue Echinocandin Azole

  13. Slide 13: VVC/RVVC Has Widespread Impact

    VVC/RVVC Has Widespread Impact OTC Topical 75% have VVC in their life time US: 4-5M suffer RVVC Rx Topical or Oral US: 4.4M visits per year 98% receive prescription

  14. Slide 14: Existing Therapies Have Significant Limitations

    Existing Therapies Have Significant Limitations 30-40% women fail acute treatment 50% relapse in RVVC No coverage of non-albicans Candida Increased risk of miscarriage (flucon) CDC guidelines recommend only using topical antifungals to treat pregnant women with VVC, including for longer periods than

  15. Slide 15: Top Desired Product Features Focus on Speed

    Top Desired Product Features Focus on Speed Resolves All Symptoms Faster Better at Getting Rid of Vaginal Yeast Better at Continuing to Keep Me Symptom-Free/ Longer Lasting Less Expensive Starts to Work Faster PERCENTAGE OF TIME RANKED 1, 2 OR 3 Even for recurrent patients, faster resolution ranked

  16. Slide 16: Phase 2 VVC Study Design

    Phase 2 VVC Study Design Objectives Safety/tolerability of CD101 Gel/Ointment Efficacy of CD101 Gel vs. CD101 Ointment vs. Fluconazole on Days 7, 14, 28 DAYS CD101 3% Gel CD101 6% Ointment Fluconazole 150mg 1 2 Dosing day 1 1 1 7 14 21 28 1 7 14 21 28 1 7 14 21 28 Efficacy 7 14 28 n=50 n=50 n=25 Myc

  17. Slide 17: Enrollment Complete; Top line data expected Q1 2017

    SUBJECTS SITES Sites Active Enrollment Top line data expected Q1 2017 Enrollment Complete

  18. Slide 18: CD101 Topical Development Plan

    CD101 Topical Development Plan Superiority in acute VVC Superiority in acute VVC Phase I/II Phase III IND I II III Phase III Dose-ranging safety & efficacy in VVC patients

  19. Slide 19: Cloudbreak: Antimicrobial Immunotherapy

    Cloudbreak™: Antimicrobial Immunotherapy Physically connects the immune system with the pathogen Vaccines Primes the immune system Therapeutics Targets the pathogen The strengths of both systems Cloudbreak™

  20. Slide 20: Cloudbreak: Inspired by Cancer Immunotherapy

    Cloudbreak: Inspired by Cancer Immunotherapy 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Binds conserved cell surface target Engages innate or adaptive immune system TARGETING MOIETY Microbe Immune Component TM EM EFFECTOR MOIETY

  21. Slide 21: CD201: First Generation Cloudbreak Antibacterial

    CD201: First Generation Cloudbreak Antibacterial EFFECTOR MOIETY TARGETING MOIETY Microbe Immune Component TM EM Gram-negative agents Gram positive agents Neutrophil recruiter Novel LPS binders Anti-virals IgM/IgG engager Macrophage recruiter NK/T cell engagers* ADCC/CDC Anti-fungals

  22. Slide 22: CD201 Trimodal Mechanism

    CD201 Trimodal Mechanism Direct kill: novel TM tightly binds conserved Gram-negative target to kill bacteria Gram-neg pathogen TM EM TM EM 1

  23. Slide 23: CD201 Trimodal Mechanism

    CD201 Trimodal Mechanism Direct kill: novel TM tightly binds conserved Gram-negative target to kill bacteria Gram-neg pathogen Immunomodulatory: EM recruits and initiates an innate immune system response 1 2 TM EM TM EM

  24. Slide 24: CD201 Trimodal Mechanism

    CD201 Trimodal Mechanism Direct kill: novel TM tightly binds conserved Gram-negative target to kill bacteria Gram-neg pathogen Immunomodulatory: EM recruits and initiates an innate immune system response 1 2 Potentiation: Enhances permeability of standard of care therapeutics to provide additional e

  25. Slide 25: CD201 TM Designed to Address mcr-1 Resistance

    CD201 TM Designed to Address mcr-1 Resistance colistin C-567 CD201 Percentage of LPS Binding >250 compounds prepared and evaluated 0 20 40 60 80 100 45% 94% 96% TM EM TM

  26. Slide 26: CD201: Intrinsic Activity vs. Resistant Pathogens

    CD201: Intrinsic Activity vs. Resistant Pathogens Gram negative pathogens: MIC90 2-4 µg/mL MIC90 for MDR isolates*: 2-16 µg/mL Low frequency of resistance (<1.5´10-9 vs. 2.4´10-9 with colistin) Higher potency compounds have since been identified MIC (µg/mL) E. coli BW25113 E. coli BW25113 (mcr-1) E.

  27. Slide 27: Robust Cloudbreak Effect in Human Blood

    Robust Cloudbreak Effect in Human Blood Test articles used at sub-MIC concentrations E. coli ATCC 25922 0 2x104 4x104 6x104 8x104 CD201 (0.01 mM) C-567 (0.01 mM) Colistin (0.01 mM) Blood alone TM EM TM P<0.0001 CFU/mL

  28. Slide 28: CD201 Efficacy: Mouse E. coli Septicemia Model

    CD201 Efficacy: Mouse E. coli Septicemia Model Mean log10 CFUs/g kidneys P<0.01 LOD 0 1 2 3 4 5 6 7 8 Vehicle + Ab (2/6) Colistin 1 mpk (6/6) CD201 3 mpk (6/6) CD201 3 mpk + Ab (12/12) Treatment (# survivors)

  29. Slide 29: CD201 Safety: 7-Day Rat Toxicology Study

    CD201 Safety: 5 Day Rat Toxicology Study CD201 showed no significant histological changes in kidney or liver colistin showed mild to moderate proximal tubule degeneration Unlike colistin, CD201 did not substantially raise urinary albumin Control CD201 25 mpk/d colistin 25 mpk/d

  30. Slide 30: Cidara's Development Pipeline

    Cidara’s Development Pipeline CD101 Cloudbreak™ IV Topical Antibacterial Antifungal Antiviral Discovery in vitro in vivo IND Enabling Phase I Phase II

  31. Slide 31: Financial Information

    Financial Information 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Summary Information At 9/30/2016 Cash, cash equivalents and marketable securities1 $115.9 million Shares issued1 16.8 million Fully-diluted shares1,2 19.1 million 1 Pro forma to include (a) net proceeds of approxi

  32. Slide 32: Expected 2017 Milestones

    Expected 2017 Milestones Program Next Milestone Expected Timing CD101 Topical Phase 2 data Q1 2017 CD101 IV Phase 2 data Q4 2017 CloudbreakTM Platform Complete CD201 IND-enabling studies H2 2017

  33. Slide 33: New Hope For Serious Infections

    New Hope For Serious Infections Corporate Presentation January 2017

  34. Slide 34: Market driven by patients visiting MD 1-2 times per year

    Market driven by patients visiting MD 1-2 times per year Source: IMS 2014 n = 20 MDs Source: US MD Survey N=20 Acute VVC infections in patients visiting the physician 1-2 times per year, with or without RVVC, drives the market

Cidara Therapeutics — Investor Presentation (January 2017) on 6ix